Fun With Mutual Fund Correlation Matrixes
Figure out which funds add diversification and which are simply duplication.
Figure out which funds add diversification and which are simply duplication.
Even if you invest through a mutual fund supermarket, you probably own at least a couple of funds from the same fund family. There's nothing wrong with that, but when funds share the same analysts and the managers work together, you can end up with funds that behave similarly.
If the funds are moving in lock step, you aren't getting much diversification from that second fund. This is where the correlation matrix comes in. It's something you can run in Morningstar Direct, our institutional-level software platform. It looks at how closely fund returns have tracked one another over the trailing three years. I've run three special correlation matrixes to help you build a portfolio. You can look to see which funds have the highest correlation so that you know which ones are most duplicative. You can also look at which have the lowest correlation so you know which have the greatest diversification.
I wouldn't buy based simply on that. You also want good funds rather than just those that offer simple diversification. (Click on each fund company name below to see the correlation matrix.)
T. Rowe Price
Let's start with T. Rowe Price's U.S. stock fund lineup. I have plugged in 15 of its largest actively managed U.S. equity funds. Let's start at the top with T. Rowe Price Blue Chip Growth (TRBCX). Scroll down column 1 and you'll see that T. Rowe Price Growth Stock (PRGFX) is a tight fit with a 1.00 correlation--the highest it can get. So, we know that owning those two large-growth funds is rather redundant. Scroll down further and you'll see that Small-Cap Value (PRSVX) has the lowest correlation at 0.91--thus, it's a good choice for diversification purposes.
For Equity-Income (VEIPX) in line 6, Value is the tightest fit, and the aggressive New Horizons at 0.92 is the least like Equity Income.
Janus
Next let's take a look at Janus where you have a distinctive growth shop in Denver and a strong value operation under the Perkins name in Chicago. No big surprise that Janus Fund has a high performance correlation with Janus Twenty (0.98) and a rather low one with Perkins Small Cap Value (JSCVX) (0.91). But it is surprising that its correlation with Janus Triton (JATTX) (0.91) is just as low as its correlation with Perkins Small Cap Value and that Global Life Sciences (JAGLX) is even lower (0.82). As Kathryn Young explains in her analysis, Triton is more risk averse than the typical Janus fund, and its focus on smaller companies has meant it has had little overlap with Janus. The correlation matrix also tells me that tech is a much bigger driver of Janus' big growth fund portfolios than health care as Global Tech (JAGTX) has much higher correlations with those funds than does Global Life Sciences.
Fidelity
Finally, how about a look at Fidelity with its array of U.S. equity funds? Let's start with Fidelity Contrafund (FCNTX) because so many people own it. For starters, it's interesting that Growth Company (FDGRX) is the only fund with a really high correlation at 0.98. It illustrates that even with the same inputs and a massive asset base to run, Will Danoff can still carve his own path. Contrafund also has the same 0.95 correlation with Low-Priced Stock (FLPSX) and Magellan (FMAGX) even though Magellan and Contrafund are both in large-growth while Low-Priced is in mid-blend. But the fund's performed least like Chuck Myers' Small Cap Value (FCPVX) and Small Cap Discovery (FSCRX). Myers is a Buffett-influenced value investor who really stands out at Fidelity, and his funds make a lot of sense for diversifying a large-growth-tilting Fidelity portfolio.
Conversely, Fidelity Fund has rather high correlation figures with nearly every fund other than Myers’ funds. That leads me to wonder if manager John Avery places similar trades to other Fidelity managers and thus ends up making the fund act like a fund with more asset bloat than it would appear from the $5 billion assets under management. Or it could be by design, as Avery runs the fund pretty close to the S&P 500.
Another Angle on Similarity
You can also put funds to the test by using our Portfolio Manager tool and testing for stock intersection. Enter two or more funds into a new portfolio and then select X-Ray and then stock intersection. This will show you how closely the funds' actual holdings are repeated.
FundInvestor Newsletter | ||
Want to hear more from the mutual fund experts? Subscribe to Morningstar FundInvestor for exclusive research, coveted analysis and proprietary ratings—neatly packaged and delivered to your inbox. | One-Year Digital Subscription 12 Issues | $125 Premium Members: $115 Easy Checkout |
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.